title: Reduced-intensity conditioning and stem cell transplantation in infants with Diamond Blackfan anemia.
authors.affiliation: Department of Pediatrics, Medical University Innsbruck, Austria roman.crazzolara@i-med.ac.at.|Tyrolean Cancer Research Institute, Innsbruck, Austria.
authors.forename: Roman
authors.initials: R
authors.lastname: Crazzolara
authors.affiliation: Department of Pediatrics, Medical University Innsbruck, Austria.
authors.forename: Gabriele
authors.initials: G
authors.lastname: Kropshofer
authors.affiliation: St. Anna Children's Hospital, Department of Pediatrics, Medical University Vienna, Austria.|Children's Cancer Research Institute, Austria.
authors.forename: Oskar A
authors.initials: OA
authors.lastname: Haas
authors.affiliation: St. Anna Children's Hospital, Department of Pediatrics, Medical University Vienna, Austria.
authors.forename: Susanne
authors.initials: S
authors.lastname: Matthes-Martin
authors.affiliation: St. Anna Children's Hospital, Department of Pediatrics, Medical University Vienna, Austria.|Children's Cancer Research Institute, Austria.
authors.forename: Leo
authors.initials: L
authors.lastname: Kager
mesh_terms: D029503:Anemia, Diamond-Blackfan / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D002066:Busulfan / Q000031:analogs & derivatives / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D019653:Myeloablative Agonists / Q000627:therapeutic use*; D013852:Thiotepa / Q000627:therapeutic use; D019172:Transplantation Conditioning / Q000379:methods*; D016896:Treatment Outcome; D014740:Vidarabine / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D019653:Myeloablative Agonists; D013852:Thiotepa; C018404:treosulfan; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine